Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Procept Biorobotics Corp (PRCT)

Procept Biorobotics Corp (PRCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,486,440
  • Shares Outstanding, K 56,390
  • Annual Sales, $ 308,050 K
  • Annual Income, $ -95,570 K
  • EBIT $ -104 M
  • EBITDA $ -97 M
  • 60-Month Beta 1.02
  • Price/Sales 4.59
  • Price/Cash Flow N/A
  • Price/Book 3.83

Options Overview Details

View History
  • Implied Volatility 77.52% (-14.20%)
  • Historical Volatility 87.03%
  • IV Percentile 74%
  • IV Rank 48.82%
  • IV High 108.86% on 11/04/25
  • IV Low 47.62% on 08/28/25
  • Expected Move (DTE 18) 2.68 (10.48%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 1,116
  • Volume Avg (30-Day) 1,479
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 21,182
  • Open Int (30-Day) 21,565
  • Expected Range 22.87 to 28.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.55
  • Number of Estimates 6
  • High Estimate -0.47
  • Low Estimate -0.60
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.85 +16.93%
on 03/02/26
28.68 -10.91%
on 03/17/26
+2.86 (+12.60%)
since 02/27/26
3-Month
19.35 +32.04%
on 02/26/26
35.40 -27.82%
on 01/06/26
-6.86 (-21.17%)
since 12/26/25
52-Week
19.35 +32.04%
on 02/26/26
66.85 -61.78%
on 06/05/25
-34.50 (-57.45%)
since 03/28/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT).  Such investors...

PRCT : 25.55 (-3.07%)
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story

PRCT : 25.55 (-3.07%)
Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems

SAN CARLOS, Calif. , March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of...

PRCT : 25.55 (-3.07%)
GDT : 38.37 (+0.28%)
ISRG : 452.77 (+0.03%)
SWAV : 334.75 (-0.02%)
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH

SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower...

PRCT : 25.55 (-3.07%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors...

PRCT : 25.55 (-3.07%)
PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales

PRCT : 25.55 (-3.07%)
Levi & Korsinsky Investigating Whether PROCEPT BioRobotics Corporation (PRCT) Misled Investors - Securities Law Violations Possible

New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics...

PRCT : 25.55 (-3.07%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT).  Such investors...

PRCT : 25.55 (-3.07%)
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy

SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform...

PRCT : 25.55 (-3.07%)
PRCT: $50.2M ADJUSTED EBITDA LOSS VS. $35M PROJECTED -- LEVI & KORSINSKY, LLP INVESTIGATES

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story

PRCT : 25.55 (-3.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use...

See More

Key Turning Points

3rd Resistance Point 27.78
2nd Resistance Point 26.97
1st Resistance Point 26.26
Last Price 25.55
1st Support Level 24.74
2nd Support Level 23.93
3rd Support Level 23.22

See More

52-Week High 66.85
Fibonacci 61.8% 48.70
Fibonacci 50% 43.10
Fibonacci 38.2% 37.49
Last Price 25.55
52-Week Low 19.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.